Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
EXJADE® (deferasirox)
www.exjade.com
(For Non U.S. Health Care Professionals Only)
EXJADE CONTACT
EXJADE® (deferasirox) is a Novartis Oncology drug indicated for the treatment of chronic iron overload due to frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.
EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
- in patients with other anemias,
- in patients aged 2 to 5 years,
- in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
EXJADE Press Releases
EXJADE Additional Materials
-
SEP-2011
Iron overload backgrounder -
SEP-2011
Thalassemia backgrounder -
SEP-2011
MDS backgrounder -
SEP-2011
Sickle cell disease backgrounder -
SEP-2011
Glossary -
SEP-2011
Long-term use of Exjade fact sheet
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
